Abstrakti
Regulatory T (Treg) cells are critical in regulating the immune response. In vitro induced Treg (iTreg) cells have significant potential in clinical medicine. However, applying iTreg cells as therapeutics is complicated by the poor stability of human iTreg cells and their variable suppressive activity. Therefore, it is important to understand the molecular mechanisms of human iTreg cell specification. We identified hypermethylated in cancer 1 (HIC1) as a transcription factor upregulated early during the differentiation of human iTreg cells. Although FOXP3 expression was unaffected, HIC1 deficiency led to a considerable loss of suppression by iTreg cells with a concomitant increase in the expression of effector T cell associated genes. SNPs linked to several immune-mediated disorders were enriched around HIC1 binding sites, and in vitro binding assays indicated that these SNPs may alter the binding of HIC1. Our results suggest that HIC1 is an important contributor to iTreg cell development and function. Ullah et al. find that HIC1 is induced during human iTreg cell differentiation. HIC1 binds to and regulates the expression of key genes during iTreg differentiation. Several autoimmune-disease-associated SNPs are enriched near HIC1 ChIP-seq peaks.
| Alkuperäiskieli | Englanti |
|---|---|
| Sivut | 2094-2106 |
| Sivumäärä | 13 |
| Julkaisu | Cell Reports |
| Vuosikerta | 22 |
| Numero | 8 |
| DOI - pysyväislinkit | |
| Tila | Julkaistu - 20 helmik. 2018 |
| OKM-julkaisutyyppi | A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä |
Rahoitus
This study was supported by Academy of Finland (AoF) grants 256355 , 258313 , 259942 , 292482 , and 294337 ; by the AoF Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012–2017 grant 250114 ; AoF Terva grant 314444 ; and by grants from the Sigrid Jusélius Foundation (SJF), the Paulo Foundation , and the Finnish Cancer Foundation . This work was supported by the AOF and the German Research Foundation (DFG; WI1722/12-1 ) Immunology Initiative “Systems Biology Approach to Molecular Mechanisms of Human TGF-β Induced iTreg Cell Differentiation and the Role of iTreg in Multiple Sclerosis” to R.L., H.L., and H.W., as well as DFG Collaborative Research Centre CRC/SFB128 “Initiating/Effector versus Regulatory Mechanisms in Multiple Sclerosis – Progress towards Tackling the Disease,” project A09, to H.W. and C.C.G. U.B. is funded by the Cluster of Excellence Cells in Motion (CiM). L.L.E. has received grants from the European Research Council (ERC; grant 677943 ), the European Union ’s Horizon 2020 research and innovation program (grant 675395 ), the AoF (grants 296801 and 304995 ), the Juvenile Diabetes Research Foundation (JDRF; grant 2-2013-32 ), the Finnish Funding Agency for Innovation (TEKES; grant 1877/31/2016 ), and SJF . We thank all the volunteer blood donors and personnel of Turku University Hospital, Department of Obstetrics and Gynecology, Maternity Ward Hospital District of Southwest Finland for the cord blood collection. Lysates from mouse Th0/iTreg cells were kindly provided by Tanja Buchacher and Mohd Moin Khan. We acknowledge Marjo Hakkarinen for technical help with the experiments and Bridget Palmer for critical reading of the manuscript. This study was supported by the Finnish Functional Genomics Centre , the University of Turku , Åbo Akademi University , and Biocenter Finland . C.C.G. has received speaking honoraria and travel expenses for attending meeting for Biogen, Genzyme, Novartis Pharma, and Bayer Health Care. Her work is funded by the German Ministry for Education and Research (BMBF; 01GI1603A ) and the German Research Foundation (DFG; GR3946/3-1 and SFB128 A09 ). H.W. receives honoraria for acting as a member of scientific advisory boards and as consultant for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma, and Sanofi-Genzyme and speaking honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma, Sanofi-Genzyme, Teva, and WebMD Global. H.W. acts as a paid consultant for Abbvie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society. Research by H.W. is funded by the BMBF ( 01FI1601E , 01GI1603A , and O1GI1603D ), DFG ( SFB128 A09 , A10 , Z02 , V and SFB1009 A03 ), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen, GlaxoSmithKline, Roche Pharma, and Sanofi-Genzyme. All other authors have no financial interest related to this work.
YK:n kestävän kehityksen tavoitteet
Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:
-
SDG 3 – Hyvä terveys ja hyvinvointi
Sormenjälki
Sukella tutkimusaiheisiin 'Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.Siteeraa tätä
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver